A Phase 1 Study of PROT-001.

NCT06981299 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: PROT-001
DRUG: Rosuvastatin 10mg
DRUG: Digoxin 0.25 mg

Sponsor

Protego Biopharma Pty Ltd